Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $540,594.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 10,011 shares of the firm’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00. Following the transaction, the director now directly owns 187,297 shares of the company’s stock, valued at $10,114,038. The trade was a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Trading Down 1.9 %

IRON stock opened at $52.24 on Monday. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $68.73. The company has a 50-day moving average price of $55.26 and a 200 day moving average price of $56.11. The stock has a market cap of $1.81 billion, a PE ratio of -13.13 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. Sell-side analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research note on Tuesday, January 21st. Stifel Nicolaus lifted their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Scotiabank lifted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. Wedbush reissued an “outperform” rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, Cantor Fitzgerald lifted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of “Buy” and a consensus price target of $93.80.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC boosted its position in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after buying an additional 503 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine in the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after buying an additional 266 shares during the period. Quest Partners LLC purchased a new stake in Disc Medicine in the 3rd quarter valued at about $131,000. Finally, Quantbot Technologies LP purchased a new stake in Disc Medicine in the 3rd quarter valued at about $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.